Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
2 minute read

Company Exploring CBG Production Signals New Era Of Commercial Success In Synthetic Biology

By Jelena Martinovic
January 10, 3:38 PM
Biotechnology company Willow Biosciences generated around $1.3m in revenues in 2023, a 60% increase from the previous year. The company has hailed 2023 as a "transformative year," citing the launch of its BioOxi bio-oxidation platform technology as one of its top achievements. The AI-driven selective hydroxylation platform removes multiple chemical steps and reduces the cost of manufacturing target molecules. The technology has enabled Willow to accelerate its path to nearer-term and potentially larger revenue opportunities while reducing operational expenses. The company also engaged in multiple partnerships with innovators and generic pharmaceutical companies, resulting in portfolio expansion and diversification. Willow underwent a restructuring of its corporate and operational framework, including consolidating operations in the San Francisco Bay area and making changes to its leadership team. In 2024, Willow plans to capitalize on the BioOxi technology platform to bring its corticosteroids program to commercial readiness and identify strategic partners for pipeline expansion and acceleration.

CANSF

Read More
2 minute read

Cannabis Giant Canopy Announces $30M Private Placement, Here’s Where The Money Will Go

By Jelena Martinovic
January 9, 1:01 PM
Canadian cannabis company Canopy Growth seeks to raise $30m in a private placement offering. The company said the move would improve its financial standing and enable it to pay down debts. Canopy Growth said in November it has reduced overall debts by C$364m to C$681m since the start of the current fiscal year. The increase in capital will provide working capital, as well as supporting other general corporate needs. The closing of the private placement under the subscription agreements is expected to occur on or about Jan. 10, 2024, subject to customary closing conditions.

CGC

Read More
2 minute read

Tilray’s Diversified Growth Strategy Is Paying Off, Here’s What’s Behind 34% YoY Revenue Increase In Q2

By Jelena Martinovic
January 9, 9:54 AM
Canadian cannabis company Tilray reported a 34% increase in revenue in its second quarter of fiscal 2024. The company reported revenue of $194 million, up from $145 million in the same period last year. Tilray's cannabis net revenue increased 35% to $67 million, while beverage alcohol net revenue increased 117% to $47 million. Distribution net revenue also rose to $67 million, compared to $60 million in the same quarter last year. The company's gross profit increased 11% to $47 million, with adjusted gross profit up 18% to $52 million. Net loss in the second quarter amounted to $46 million, compared to a net loss of $62 million in the same period last year. Adjusted EBITDA stood at $10.1 million, down from $11 million in Q2 2023.

TLRY